For this analysis, we selected a timepoint (Day 22) when the therapeutic effect of the single treatments was fading, while mice receiving CTX + Sl-IFN were experiencing further tumor shrinkage, implying possible immune-related effects. The gene discussed is IFNA1; the disease is neoplasm.